Compare Gilead Sciences, Inc. (GILD) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United Parcel Service Inc — how do they compare? Gilead Sciences, Inc. trades at $133.29 (market cap $163.51B), while United Parcel Service Inc trades at $115.36 (market cap $96.00B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and United Parcel Service Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals.
| GILD | UPS | |
|---|---|---|
Market Cap | $163.51B | $96.00B |
Sector | Health | Industrials |
52-Week High | $155.80 | $120.00 |
52-Week Low | $108.22 | $82.58 |
Enterprise Value | $178.05B | $118.86B |
Dividend Yield | 2.49% | 5.81% |
Volume | — | 2,288,643 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
UPS trades at $113.67, up 0.69% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue has moderated from $100.3B in 2022 to $88.7B in 2025, but profitability remains solid with a 5.94% net margin and strong ROE of 33.41%. The company is investing in healthcare logistics and AI to boost efficiency, with Q2 2026 earnings due July 28.
The outlook is mixed: valuation is reasonable (P/E 18.28), but revenue headwinds and Amazon's logistics expansion pose risks. Analyst consensus is neutral with a $112 price target, slightly below the current price. Dividend sustainability is a focus amid competitive pressures, though cost controls support cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
